Last reviewed · How we verify

Depodur

Goodman, Evan, M.D. · FDA-approved active Small molecule

Depodur is a Small molecule drug developed by Goodman, Evan, M.D.. It is currently FDA-approved. Also known as: Traditional, morphine sulfate extended-release liposome injection.

At a glance

Generic nameDepodur
Also known asTraditional, morphine sulfate extended-release liposome injection
SponsorGoodman, Evan, M.D.
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Depodur

What is Depodur?

Depodur is a Small molecule drug developed by Goodman, Evan, M.D..

Who makes Depodur?

Depodur is developed and marketed by Goodman, Evan, M.D. (see full Goodman, Evan, M.D. pipeline at /company/goodman-evan-m-d).

Is Depodur also known as anything else?

Depodur is also known as Traditional, morphine sulfate extended-release liposome injection.

What development phase is Depodur in?

Depodur is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing